A 57-year-old male, diagnosed with a 1.2cm diameter non-small cell lung tumor in the right upper lobe and deemed unfit for surgery as a result of severe emphysema, was the first patient to receive the pioneering radiotherapy treatment at the hospital in early September... Varian Medical Systems' Press Release -
Blog Archive
-
▼
2008
(297)
-
▼
October
(25)
- Vision-Sciences : Advanced, Video-Based Bronchosco...
- Varian Medical Systems : Clinicians in Netherlands...
- Quark : Publication of Study on Use of siRNA again...
- Aerovance : Aerovant Inhalation Powder is Well To...
- Aires Pharmaceuticals : Key Technology License Agr...
- Novartis and Nektar Therapeutics Pulmonary Business
- Ranbaxy & GSK : IND APPLICATION TO DCGI FOR RESPIR...
- Bayer Schering Pharma : Progress in Clinical Progr...
- APT Pharmaceuticals : Phase III Trial of Inhaled...
- NeoGenomics Laboratories Extends Its Cancer Testin...
- BioView : Interim Results of Early Detection Lung ...
- Novartis : Early data show potential for imatinib ...
- Alfacell's ONCONASE(R) Targets siRNA : Paper in Ce...
- Neotropix : Expansion of On-going Clinical Trial f...
- Health Hero Network : Recertification from Nationa...
- Teva Pharmaceutical : Proair® HFA, the Market Lead...
- Gemin X : Key U.S. Patent Issued for Obatoclax
- Kuros Biosurgery and Aeris Therapeutics : Exclusiv...
- REGENERX : RGN-457 for Cystic Fibrosis
- Gilead Complete Response Letter from U.S. Food and...
- MD Biosciences : Preclinical Disease Models at the...
- Medical Acoustics : Results on Efficacy of Medical...
- Arriva Pharmaceuticals : Protein Production Patent
- Dynavax Technologies : Milestone from AstraZeneca
- Advanced Life Sciences : NDA Submission for Cethr...
-
▼
October
(25)
Oct 24, 2008
Varian Medical Systems : Clinicians in Netherlands Treat Lung Cancer Patients Using New RapidArc Radiotherapy Technology
Oct. 14, 2008 - Doctors in the Netherlands have used RapidArc technology from Varian Medical Systems (NYSE: VAR) to treat four early stage lung cancer patients in what is believed to be among the world's first treatments of their kind. Clinicians at VU University Medical Center in Amsterdam now plan to replace conventional stereotactic radiotherapy treatments with RapidArc for all such patients.